|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang L, Zhu MJ, Ren AM, Wu HF, Han WM, Tan
RY and Tu RQ: A ten-microRNA signature identified from a
genome-wide microRNA expression profiling in human epithelial
ovarian cancer. PLoS One. 9:e964722014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Walentowicz P, Sadlecki P, Krintus M,
Sypniewska G, Mankowska-Cyl A, Grabiec M and Walentowicz-Sadlecka
M: Serum anti-müllerian hormone levels in patients with epithelial
ovarian cancer. Int J Endocrinol. 2013(517239)2013. View Article : Google Scholar
|
|
4
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: The impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim PS, Djazayeri S and Zeineldin R: Novel
nanotechnology approaches to diagnosis and therapy of ovarian
cancer. Gynecol Oncol. 120:393–403. 2011. View Article : Google Scholar
|
|
6
|
Gilks CB and Prat J: Ovarian carcinoma
pathology and genetics: Recent advances. Hum Pathol. 40:1213–1223.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Landen CN Jr, Birrer MJ and Sood AK: Early
events in the pathogenesis of epithelial ovarian cancer. J Clin
Oncol. 26:995–1005. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kurman RJ: Origin and molecular
pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol.
24(Suppl 10): x16–x21. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bennett JA, Dong F, Young RH and Oliva E:
Clear cell carcinomas of the ovary: Evaluation of prognostic
parameters based on a clinicopathologic analysis of 100 cases.
Histopathology. 66:808–815. 2015. View Article : Google Scholar
|
|
10
|
Kinose Y, Sawada K, Nakamura K and Kimura
T: The role of microRNAs in ovarian cancer. Biomed Res Int.
2014(249393)2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oom AL, Humphries BA and Yang C:
MicroRNAs: Novel Players in cancer diagnosis and therapies. Biomed
Res Int. 2014(959461)2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang B, Pan X, Cobb GP and Anderson TA:
MicroRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar
|
|
13
|
Ventura A and Jacks T: MicroRNAs and
cancer: Short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang L, Volinia S, Bonome T, Calin GA,
Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K,
et al: Genomic and epigenetic alterations deregulate microRNA
expression in human epithelial ovarian cancer. Proc Natl Acad Sci
USA. 105:7004–7009. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
van Jaarsveld MT, Helleman J, Berns EM and
Wiemer EA: MicroRNAs in ovarian cancer biology and therapy
resistance. Int J Biochem Cell Biol. 42:1282–1290. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Eitan R, Kushnir M, Lithwick-Yanai G,
David MB, Hoshen M, Glezerman M, Hod M, Sabah G, Rosenwald S and
Levavi H: Tumor microRNA expression patterns associated with
resistance to platinum based chemotherapy and survival in ovarian
cancer patients. Gynecol Oncol. 114:253–259. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kandukuri SR and Rao J: FIGO 2013 staging
system for ovarian cancer: What is new in comparison to the 1988
staging system? Curr Opin Obstet Gynecol. 27:48–52. 2015.
View Article : Google Scholar
|
|
18
|
Mavridis K, Stravodimos K and Scorilas A:
Downregulation and prognostic performance of microRNA 224
expression in prostate cancer. Clin Chem. 59:261–269. 2013.
View Article : Google Scholar
|
|
19
|
Zhao JY, Liu CQ, Zhao HN, Ding YF, Bi T,
Wang B, Lin XC, Guo G and Cui SY: Synchronous detection of miRNAs,
their targets and downstream proteins in transferred FFPE sections:
Applications in clinical and basic research. Methods. 58:156–163.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu X, Zhang X, Bi T, Ding Y, Zhao J, Wang
C, Jia T, Han D, Guo G, Wang B, et al: MiRNA expression signature
for potentially predicting the prognosis of ovarian serous
carcinoma. Tumour Biol. 34:3501–3508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vilming Elgaaen B, Olstad OK, Haug KB,
Brusletto B, Sandvik L, Staff AC, Gautvik KM and Davidson B: Global
miRNA expression analysis of serous and clear cell ovarian
carcinomas identifies differentially expressed miRNAs including
miR-200c-3p as a prognostic marker. BMC Cancer. 14(80)2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee H, Park CS, Deftereos G, Brusletto B,
Sandvik L, Staff AC, Gautvik KM and Davidson B: MicroRNA expression
in ovarian carcinoma and its correlation with clinicopathological
features. World J Surg Oncol. 10(174)2012. View Article : Google Scholar
|
|
23
|
Banno K, Yanokura M, Iida M, Adachi M,
Nakamura K, Nogami Y, Umene K, Masuda K, Kisu I, Nomura H, et al:
Application of microRNA in diagnosis and treatment of ovarian
cancer. Biomed Res Int. 2014(232817)2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot
CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, et al: Integrated
analyses identify a master microRNA regulatory network for the
mesenchymal subtype in serous ovarian cancer. Cancer Cell.
23:186–199. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Streicher KL, Zhu W, Lehmann KP,
Georgantas RW, Morehouse CA, Brohawn P, Carrasco RA, Xiao Z, Tice
DA, Higgs BW, et al: A novel oncogenic role for the miRNA-506-514
cluster in initiating melanocyte transformation and promoting
melanoma growth. Oncogene. 31:1558–1570. 2012. View Article : Google Scholar
|
|
26
|
Bagnoli M, De Cecco L, Granata A,
Nicoletti R, Marchesi E, Alberti P, Valeri B, Libra M, Barbareschi
M, Raspagliesi F, et al: Identification of a chrXq27.3 microRNA
cluster associated with early relapse in advanced stage ovarian
cancer patients. Oncotarget. 2:1265–1278. 2011. View Article : Google Scholar
|
|
27
|
Lynch HT, Casey MJ, Snyder CL, Bewtra C,
Lynch JF, Butts M and Godwin AK: Hereditary ovarian carcinoma:
Heterogeneity, molecular genetics, pathology, and management. Mol
Oncol. 3:97–137. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Koshiyama M, Matsumura N and Konishi I:
Recent concepts of ovarian carcinogenesis: Type I and type II.
Biomed Res Int. 2014(934261)2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Streicher KL, Zhu W, Lehmann KP,
Georgantas RW, Morehouse CA, Brohawn P, Carrasco RA, Xiao Z, Tice
DA, Higgs BW, et al: A novel oncogenic role for the miRNA-506-514
cluster in initiating melanocyte transformation and promoting
melanoma growth. Oncogene. 31:1558–1570. 2012. View Article : Google Scholar
|
|
30
|
Guo QJ, Mills JN, Bandurraga SG, Nogueira
LM, Mason NJ, Camp ER, Larue AC, Turner DP and Findlay VJ:
MicroRNA-510 promotes cell and tumor growth by targeting
peroxiredoxin1 in breast cancer. Breast Cancer Res. 15:R702013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Patnaik SK, Kannisto E, Knudsen S and
Yendamuri S: Evaluation of microRNA expression profiles that may
predict recurrence of localized stage I non-small cell lung cancer
after surgical resection. Cancer Res. 70:36–45. 2010. View Article : Google Scholar
|
|
32
|
Chen W, Tang Z, Sun Y, Zhang Y, Wang X,
Shen Z, Liu F and Qin X: miRNA expression profile in primary
gastric cancers and paired lymph node metastases indicates that
miR-10a plays a role in metastasis from primary gastric cancer to
lymph nodes. Exp Ther Med. 3:351–356. 2012.PubMed/NCBI
|
